Drugs / ABO2102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06577532 | Sep 2024 → Dec 2026 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07455617 | Mar 2026 → Jun 2029 expected | metastatic neoplasm | Suzhou Abogen Biosciences Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Abogen Biosciences Co. Ltd. | Regulatory Abogen Received Dual IND Approvals for KRAS mRNA Vaccine in China and the United States abogenbio.com ↗
On August 4, 2025, Abogen Biosciences announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) granted Investigational New Drug (IND) approval for its novel KRAS mRNA cancer vaccine ABO2102, targeting five common mutations. |
| 2025-05-14 | Abogen Biosciences Co. Ltd. | Regulatory Abogen Received FDA IND Approval for KRAS mRNA Vaccine abogenbio.com ↗
On May 9, 2025, Abogen Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its novel KRAS mRNA cancer vaccine ABO2102, targeting five common KRAS mutations. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Abogen Biosciences Co. Ltd. | Abogen Received Dual IND Approvals for KRAS mRNA Vaccine in China and the United States abogenbio.com ↗ |
| 2025-05-14 | Abogen Biosciences Co. Ltd. | Abogen Received FDA IND Approval for KRAS mRNA Vaccine abogenbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07455617 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA encoding mutant KRAS neoantigens” NCT06577532 ↗ |
| Route | Intramuscular | “administrated intramuscularly” NCT06577532 ↗ |